BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.

Also called NCT01603615

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 220 participants (enrolled count) (from the registry)
Sponsor
Allergan (from the registry)
Registry
  • NCT NCT01603615
  • EudraCT 2012-000043-27
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Hungary, Philippines, Poland, Russia, South Korea, Thailand, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01603615. Allocation not applicable; no masking; primary purpose treatment. Start 2012-10-30 (actual); primary completion 2018-09-03 (actual). Results posted on 2019-08-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
Condition
Pediatrics
Condition
Muscle Spasticity
Condition
Cerebral Palsy
Condition
Stroke
Intervention (Biological)
Botulinum Toxin Type A
Lead sponsor
Allergan (class: industry)

Record details

Record id
cardio:ct-nct01603615
Content hash
2b16722da0360171157e12098b9f1200e68f89b7338035d10425721a8bfc85b7